Catalyst Dossier · compiled by CeliA 🧫

BeOne Medicines Ltd. (BEIGF)

Biotechnology · market cap $40.9B · as of 2026-07-09

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-09-22 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

BeOne Medicines Ltd. (BEIGF) is a global biotechnology company with approximately 11,000 employees and a market cap of roughly $40.9 billion. Its pipeline centers on hematologic malignancies, with lead assets sonrotoclax (Phase 3, Waldenstrom Macroglobulinemia), zanubrutinib (Phase 3, Chronic Lymphocytic Leukemia), and BGB-16673 (Phase 2, B-cell malignancies). Two Phase 2 readouts are expected in the second half of 2026, making this a catalyst-rich window.

The catalyst path

2026-09-22 (est.)Phase 2 · Sonrotoclaximp 7/10
2026-11-15 (est.)Phase 2 · BGB-16673imp 7/10
2026-11-15 (est.)Phase 2 · Dexamethasoneimp 7/10
2026-12-01 (est.)Phase 2 · Zanubrutinibimp 7/10
2026-12-01 (est.)Phase 2 · bendamustineimp 7/10
2026-12-31 (est.)Phase 2 · Fludarabineimp 7/10
2027-02-15 (est.)Phase 2 · Zanubrutinibimp 7/10
2027-03-15 (est.)Phase 3 · bendamustineimp 9/10

Pipeline

Asset	Phase	Indication
PD-1/PD-L1 inhibitors	Phase 2	Borderline Resectable Carcinoma
ZW25 (Zanidatamab)	Phase 2	HER2-amplified Biliary Tract Cancers
Tacabrutideg	Phase 2	Chronic Lymphocytic Leukemia
BGB-16673	Phase 3	B-cell Malignancy
Sonrotoclax	Phase 3	Waldenstrom Macroglobulinemia
Zanubrutinib	Phase 3	Chronic Lymphocytic Leukemia
Tislelizumab	Phase 3	Colorectal Cancer
CAR-T Cell Therapy	Phase 2	Mantle Cell Lymphoma
Blinatumomab	Phase 2	Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Fludarabine	Phase 2	Recurrent Transformed Chronic Lymphocytic Leukemia
BGB-11417	Phase 2	Acute Myeloid Leukemia
bendamustine	Phase 3	Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Dexamethasone	Phase 2	Relapsed/Refractory Multiple Myeloma
Tacrolimus	Phase 3	Primary Membranous Nephropathy
Oxaliplatin	Phase 3	Advanced Unresectable Gastric Adenocarcinoma
Leucovorin	Phase 2	Gastroesophageal Adenocarcinoma

Price & technical context

3-month

+58.6%

6-month

+58.6%

12-month

+63.2%

52-wk range

$13.68–$25.29

vs 50-day MA

+22.7%

vs 200-day MA

+47.3%

Realized vol

58.9%

Max drawdown

-23.0%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BEIGF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 16 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.